b. PT/OT/SPL services performed, by a qualified clinician employed by a physician/NPP or physician/NPP group without a Medicare NPI should be reported to Medicare under the physicians/NPPs Medicare NPI, with an appropriate HCPCS/CPT code and the appropriate therapy modifier (GN, GO, GP).
ity.18,19 The Abl SH2 domain forms an extensive interaction interface with the C-terminal lobe of the kinase domain that is stabilized by an interlocking network of hydrogen bonds (Fig. 2).18 Due to the different relative orientation of the 2 kinase lobes in Src and Abl, the SH2 domain approaches the kinase domain much closer in Abl (Fig. 2). The SH2âC-
Moreover, the BCR-ABL protein inhibits DNA repair, causing genomic instability and making the cell more susceptible to developing further genetic abnormalities. The action of the BCR-ABL protein is the pathophysiologic cause of chronic myelogenous leukemia. With improved understanding of the nature of the BCR-ABL protein and its action as a tyrosine kinase, targeted therapies (the first of which was imatinib) that specifically inhibit the activity of the BCR-ABL protein have been developed.